ATHX 71% v265M c.325 f263,9M H0.388 sucks that I sold this

New Post Public Reply Private Reply Replies (1) Message Board
znewcar1
334
ATHX 71% v265M c.325 f263,9M H0.388 sucks that I sold this when I did.

Athersys Inc. (ATHXQ) Stock Research Links

ATHXQ Board Company Profile Buy Rating Time & Sales News Filings Financials
The majority of my post are the top 20% gainer! To decode them its (ticker ID, % Changed, Volume, Close price and Float) I typically put V,C&F as a prefix to that number and use K, M and B as a suffix (Kilo, Million & Billion) for volume and float. I may also use S for Support and R for Resistance.

I (Znewcar1) do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
I will not and cannot be held liable for any actions you take as a result of anything you read here.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

transcosmos Secures Special Jury Award for Outstanding Strategy

Updated Category News Views 157

Transcosmos Achieves Recognition at Contact Center Awards Recognized for clear, goal-oriented strategy working together with clients. TOKYO /PRNewswire/ -- transcosmos is thrilled to share that the company has been awarded the Special Jury Award in the Strategy category at the Contact Center Awards 2025. This prestigious event is sponsored by the Editorial Office of...

Continue Reading
HCW Biologics Partners with WY Biotech for Innovative Licensing Deal

Updated Category News Views 121

HCW Biologics Collaborates with WY Biotech on a Licensing Agreement HCW Biologics has taken an exciting step forward by entering into a license agreement with WY Biotech for a transformative preclinical immunotherapeutic product candidate. This partnership positions both companies to harness innovative technologies in the biopharmaceutical landscape. Financial Aspects of...

Continue Reading
Bucked Up® Unveils Hunt: Orange Cream—Limited Edition

Updated Category News Views 14

The Buzz Behind Bucked Up®'s Limited-Edition Flavor You know, there's caffeine, and then there's Bucked Up®'s caffeine kick—it’s a whole different animal. But now they’ve spiced things up a notch with their new Hunt: Orange Cream flavor. It’s plastered on every product from their line, from Bucked Up® to the wacky-named Woke AF®. Feels like they’re saying,...

Continue Reading
Transform Your Investment: The Growth of SPS Commerce Over Time

Updated Category News Views 53

The Impressive Growth of SPS Commerce SPS Commerce (NASDAQ: SPSC) has carved out a strong position in the market, consistently providing remarkable returns. Over the last 15 years, this company has outpaced average market growth by a staggering 13.26% each year, resulting in an average annual return of 25.11%. As of now, SPS Commerce enjoys a robust market capitalization...

Continue Reading
Exploring QIAGEN's Commitment to Newborn Genomic Sequencing

Updated Category News Views 106

Innovating Genomic Sequencing for Newborns QIAGEN (NYSE: QGEN) is making significant strides in the field of genomic medicine by partnering with Genomics England on a remarkable initiative aimed at sequencing the genomes of newborns. This pioneering effort seeks to screen for over 200 genetic conditions, facilitating early diagnosis and intervention for rare health...

Continue Reading